OM-85

ApprovedSmall molecule

OOM Pharma SA

OM-85 is one of 49 small molecule programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

WheezingActive, not recruiting

Respiratory Tract InfectionApproved

Active, not recruiting

WheezingPhase 2

Active, not recruiting

Competition

Competitive Landscape

80 competitors in Respiratory Tract Infection

#DrugCompanyPhaseTrials

Levaquin

WWim Janssens

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

1 4

Bacille Calmette-Guérin

Roche

Approved

1 5

Veklury

Gilead

Phase 2

1 6

Quietus

Merck & Co.

Phase 2

1 7

Rapivab

BBioCryst Pharmaceuticals

Phase 3

1 8

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 9

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 10

OM-85

OOM Pharma SA

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalActive, not recruiting

Respiratory Tract Infection

NCT05677763

Phase 2Active, not recruiting

Wheezing

NCT05857930

Clinical

Trials by Indication[1]

Respiratory tract infection2 trials

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

Active, not recruiting·OOM Pharma SA·Phase 4·NCT05677763·525 enrolled

Effect of OM-85 on Respiratory Tract Infections and Adenoid Tissue in Children With Adenoid Hypertrophy

Unknown status·—·Phase 4·NCT03243565·68 enrolled

Wheezing1 trial

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

Active, not recruiting·OOM Pharma SA·Phase 2·NCT05857930·296 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for OM-85. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OM-85 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OM-85. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OM Pharma SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOM Pharma SA

OM-85

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Respiratory tract infection2 trials

Wheezing1 trial

References

Drug Info

Quick Facts

Related News